Latest press releases

The story of

TreeFrog Therapeutics


Cell therapy for all

Incorporated in Bordeaux in 2018, TreeFrog Therapeutics is a French-based biotech startup aimed at making cell therapies safer, more efficient, more accessible and more affordable for millions of patients.



The C-Stem™ technology introduces:

  • A highly scalable manufacturing process allowing for the mass production of cell therapies based on induced pluripotent stem cells (iPSC), while drastically reducing costs.

  • A new quality standard for iPSC-derived cell therapy products

  • A 3D transplantation format enhancing therapeutic outcomes

Going for mass market

TreeFrog is advancing a pipeline of cell therapies targeting high-burden and currently incurable chronic and degenerative diseases, including blood and immune disorders, Parkinson’s disease, as well as heart and liver failure.

Key figures
meeting in Geneva

TreeFrog Therapeutics was co-founded by Kevin Alessandri, PhD, an expert in 3D-printed microfluidics, and Maxime Feyeux, a stem cell biologist who was one of first PhD students worldwide to work on pluripotent stem cells.

raised since inc. in 2018
$ 0 M

Awarded with top innovation grants at French & European level (i-LAB, i-Nov, EIC accelerator), TreeFrog also attracted over $82M in private investments over the past 3 years.

froggies worldwide
0 +

Bringing together physicists, cell biologists and bioproduction engineers
self-dubbed the froggies, the TreeFrog team will grow 3-fold over the next 3 years, expanding in France,  USA and Japan.

ongoing contracts
0 +

Focused on bringing the benefits of C-Stem™ as fast as possible to patients, TreeFrog is partnering with market leaders in EU, USA and Japan to develop cell therapies with mass-market potential.

The latest

They talked about us


Contact us !